Financial Result for quarter and year ended on 31st March 2025
RPGLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.8 pts more than Nifty Microcap 250 and 1.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
RPG Life Sciences Limited has submitted its audited financial results for the fourth quarter (Q4) and the full financial year ending 31st March 2025 to the stock exchanges. This is a standard periodic compliance filing that discloses the company's revenue, expenses, operating profit, net profit, and earnings per share for both the standalone quarter and the twelve-month period. The filing typically includes a statement of profit and loss, balance sheet highlights, and segment-wise performance, along with the auditor's report. Investors use these numbers to track the pharma company's growth trajectory, margin trends, and overall financial health versus prior periods and Street estimates.
For shareholders, this is the official confirmation of how the company performed in FY25 — the actual impact on the stock will hinge on whether revenue growth, profitability and margins came in above or below market expectations. Watch for the year-on-year comparison and management commentary for forward-looking cues.